Literature DB >> 22874673

The P's and Q's of cellular PrP-Aβ interactions.

David Westaway1, Jack H Jhamandas.   

Abstract

Prion disease research has opened up the "black-box" of neurodegeneration, defining a key role for protein misfolding wherein a predominantly alpha-helical precursor protein, PrP (C), is converted to a disease-associated, β-sheet enriched isoform called PrP (Sc). In Alzheimer disease (AD) the Aβ peptide derived from the β-amyloid precuror protein APP folds in β-sheet amyloid. Early thoughts along the lines of overlap may have been on target, (1) but were eclipsed by a simultaneous (but now anachronistic) controversy over the role of PrP (Sc) in prion diseases. (2) (,) (3) Nonetheless, as prion diseases such as Creutzfeldt-Jakob Disease (CJD) are themselves rare and can include an overt infectious mode of transmission, and as familial prion diseases and familial AD involve different genes, an observer might reasonably have concluded that prion research could occasionally catalyze ideas in AD, but could never provide concrete overlaps at the mechanistic level. Surprisingly, albeit a decade or three down the road, several prion/AD commonalities can be found within the contemporary literature. One important prion/AD overlap concerns seeded spread of Aβ aggregates by intracerebral inoculation much like prions, (4) and, with a neuron-to-neuron 'spreading' also reported for pathologic forms of other misfolded proteins, Tau (5) (,) (6) and α-synuclein in the case of Parkinson Disease. (7) (,) (8) The concept of seeded spread has been discussed extensively elsewhere, sometimes under the rubric of "prionoids" (9), and lies outside the scope of this particular review where we will focus upon PrP (C). From this point the story can now be subdivided into four strands of investigation: (1) pathologic effects of Aβ can be mediated by binding to PrP (C), (10) (2) the positioning of endoproteolytic processing events of APP by pathologic (β-cleavage + γ-cleavage) and non-pathologic (α-cleavage + γ-cleavage) secretase pathways is paralleled by seemingly analogous α- and β-like cleavage of PrP (C) (Fig. 1) (3) similar lipid raft environments for PrP (C) and APP processing machinery, (11) (-) (13) and perhaps in consequence, overlaps in repertoire of the PrP (C) and APP protein interactors ("interactomes"), (14) (,) (15) and (4) rare kindreds with mixed AD and prion pathologies. (16) Here we discuss confounds, consensus and conflict associated with parameters that apply to these experimental settings.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22874673      PMCID: PMC3609064          DOI: 10.4161/pri.20675

Source DB:  PubMed          Journal:  Prion        ISSN: 1933-6896            Impact factor:   3.931


  59 in total

1.  Memory impairment in transgenic Alzheimer mice requires cellular prion protein.

Authors:  David A Gimbel; Haakon B Nygaard; Erin E Coffey; Erik C Gunther; Juha Laurén; Zachary A Gimbel; Stephen M Strittmatter
Journal:  J Neurosci       Date:  2010-05-05       Impact factor: 6.167

2.  Ionic mechanisms of action of prion protein fragment PrP(106-126) in rat basal forebrain neurons.

Authors:  Kwai Alier; Zongming Li; David Mactavish; David Westaway; Jack H Jhamandas
Journal:  J Neurosci Res       Date:  2010-08-01       Impact factor: 4.164

Review 3.  The transcellular spread of cytosolic amyloids, prions, and prionoids.

Authors:  Adriano Aguzzi; Lawrence Rajendran
Journal:  Neuron       Date:  2009-12-24       Impact factor: 17.173

4.  Axonal prion protein is required for peripheral myelin maintenance.

Authors:  Juliane Bremer; Frank Baumann; Cinzia Tiberi; Carsten Wessig; Heike Fischer; Petra Schwarz; Andrew D Steele; Klaus V Toyka; Klaus-Armin Nave; Joachim Weis; Adriano Aguzzi
Journal:  Nat Neurosci       Date:  2010-01-24       Impact factor: 24.884

5.  The alpha-secretase-derived N-terminal product of cellular prion, N1, displays neuroprotective function in vitro and in vivo.

Authors:  Marie-Victoire Guillot-Sestier; Claire Sunyach; Charlotte Druon; Sabine Scarzello; Frédéric Checler
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

6.  Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein.

Authors:  Claudia Balducci; Marten Beeg; Matteo Stravalaci; Antonio Bastone; Alessandra Sclip; Emiliano Biasini; Laura Tapella; Laura Colombo; Claudia Manzoni; Tiziana Borsello; Roberto Chiesa; Marco Gobbi; Mario Salmona; Gianluigi Forloni
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-19       Impact factor: 11.205

7.  Role of ADAMs in the ectodomain shedding and conformational conversion of the prion protein.

Authors:  David R Taylor; Edward T Parkin; Sarah L Cocklin; James R Ault; Alison E Ashcroft; Anthony J Turner; Nigel M Hooper
Journal:  J Biol Chem       Date:  2009-06-29       Impact factor: 5.157

8.  Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells.

Authors:  Kelvin C Luk; Cheng Song; Patrick O'Brien; Anna Stieber; Jonathan R Branch; Kurt R Brunden; John Q Trojanowski; Virginia M-Y Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-05       Impact factor: 11.205

9.  Prion protein and Abeta-related synaptic toxicity impairment.

Authors:  Anna Maria Calella; Mélissa Farinelli; Mario Nuvolone; Osvaldo Mirante; Rita Moos; Jeppe Falsig; Isabelle M Mansuy; Adriano Aguzzi
Journal:  EMBO Mol Med       Date:  2010-08       Impact factor: 12.137

10.  Interactome analyses identify ties of PrP and its mammalian paralogs to oligomannosidic N-glycans and endoplasmic reticulum-derived chaperones.

Authors:  Joel C Watts; Hairu Huo; Yu Bai; Sepehr Ehsani; Amy Hye Won Jeon; Amy Hye Won; Tujin Shi; Nathalie Daude; Agnes Lau; Rebecca Young; Lei Xu; George A Carlson; David Williams; David Westaway; Gerold Schmitt-Ulms
Journal:  PLoS Pathog       Date:  2009-10-02       Impact factor: 6.823

View more
  8 in total

1.  A roadmap for investigating the role of the prion protein in depression associated with neurodegenerative disease.

Authors:  Danielle Beckman; Rafael Linden
Journal:  Prion       Date:  2016-03-03       Impact factor: 3.931

Review 2.  The neurodegeneration in Alzheimer disease and the prion protein.

Authors:  Gianluigi Forloni; Alessandra Sclip; Tiziana Borsello; Claudia Balducci
Journal:  Prion       Date:  2013-01-01       Impact factor: 3.931

Review 3.  Therapies for human prion diseases.

Authors:  Peter K Panegyres; Elizabeth Armari
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

Review 4.  APP Receptor? To Be or Not To Be.

Authors:  Carole Deyts; Gopal Thinakaran; Angèle T Parent
Journal:  Trends Pharmacol Sci       Date:  2016-01-31       Impact factor: 14.819

5.  Ca(2+)/calmodulin-dependent protein kinase II interacts with group I metabotropic glutamate and facilitates receptor endocytosis and ERK1/2 signaling: role of β-amyloid.

Authors:  Fitore Raka; Andrea R Di Sebastiano; Stephanie C Kulhawy; Fabiola M Ribeiro; Christina M Godin; Fabiana A Caetano; Stephane Angers; Stephen S G Ferguson
Journal:  Mol Brain       Date:  2015-03-26       Impact factor: 4.041

6.  Single-molecule imaging reveals that small amyloid-β1-42 oligomers interact with the cellular prion protein (PrP(C)).

Authors:  Kristina A Ganzinger; Priyanka Narayan; Seema S Qamar; Laura Weimann; Rohan T Ranasinghe; Adriano Aguzzi; Christopher M Dobson; James McColl; Peter St George-Hyslop; David Klenerman
Journal:  Chembiochem       Date:  2014-10-07       Impact factor: 3.164

7.  Endoproteolysis of cellular prion protein by plasmin hinders propagation of prions.

Authors:  Charles E Mays; Trang H T Trinh; Glenn Telling; Hae-Eun Kang; Chongsuk Ryou
Journal:  Front Mol Neurosci       Date:  2022-09-02       Impact factor: 6.261

8.  Heart fatty acid binding protein and Aβ-associated Alzheimer's neurodegeneration.

Authors:  Rahul S Desikan; Wesley K Thompson; Dominic Holland; Christopher P Hess; James B Brewer; Henrik Zetterberg; Kaj Blennow; Ole A Andreassen; Linda K McEvoy; Bradley T Hyman; Anders M Dale
Journal:  Mol Neurodegener       Date:  2013-10-02       Impact factor: 14.195

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.